Abstract
A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT2C receptor.
Original language | English (US) |
---|---|
Pages (from-to) | 772-773 |
Number of pages | 2 |
Journal | ACS Chemical Neuroscience |
Volume | 1 |
Issue number | 12 |
DOIs | |
State | Published - Dec 15 2010 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Physiology
- Cognitive Neuroscience
- Cell Biology